Due to recent developments in
in vivo oligonucleotide delivery systems, RNA-based therapeutic approaches are becoming more and more enticing. Hence, next to e.g. RNA-based vaccines, five silencing RNA (siRNA) drugs have been clinically approved (patisiran, givosiran, lumasiran, inclisiran, and vutrisiran) that act via the mechanism of RNA interference (RNAi) to downregulate specific genes [1-5]. All five siRNA drugs on the market treat metabolic or neurodegenerative diseases. As an alternative application, targeting cancer cells by downregulation of genes that are essential for e.g. mitosis would be attractive as well. In that way, also proteins that are considered undruggable could be targeted. However, similar to small molecular drug approaches, the mere targeting of mitosis and thus fast dividing cells, results in dose-limiting side effects concerning non-cancerous cells that rely on fast proliferation, resulting in myelosuppression, cytopenia, hepatotoxicity, etc. One possible solution to increase cancer selectivity is the application of prodrugs that get activated in a specific cancer microenvironment or upon an external trigger. Accordingly, few examples of siRNA prodrugs have been reported [6-8]. Following this approach we have already developed ROS-responsive siRNAs that get activated by elevated H
2O
2 concentrations [
9], a hallmark of many cancers [
10]. In addition, we reported on red light-responsive siRNAs (
Figure 1), in which the passenger strand is modified with a photosensitizer that generates
1O
2 upon red-light irradiation. The on-demand generated
1O
2 cleaves the 9-anthracenyl promoiety on the antisense strand, yielding the active siRNA. While, the activation is efficient, side effects by these harsh oxidative conditions are to be expected, especially for
in vivo applications. That can be one of the reasons why this system has never been applied
in vivo. In search of alternative promoieties, which are not activated under strong oxidative conditions, we explored azobenzenes. The application of azobenzene triggers in a biological context comes with some challenges, as two distinct processes can be initiated, the first one being photoisomerization and the second one being reduction. Photoisomerization of azobenzenes is in most cases triggered by UV light, which is toxic to cells and does not show significant tissue penetration. Nevertheless, some stable azobenzenes were successfully applied in living cells or
in vivo to activate certain processes (e.g. disassembly of complex biomolecules) by photoswitching to the
cis isomer [11-13]. Exploiting the second process, few approaches have also been developed towards reducible azobenzenes, e.g., as sensors of hypoxia [14, 15]. For this study, we aimed for a stable azobenzene moiety to avoid unspecific intracellular reduction of the siRNA prodrug. However, upon external trigger, the promoiety should be reduced efficiently. We, therefore, selected electron-rich azobenzene “RF” (
Scheme 1), which was shown to be non-cleavable under conditions mimicking the cellular environment [
16]. We hoped that this residue still will be photo reducible in the presence of previously reported photocatalysts Sn(IV)(pyropheophorbide a)dichloride (SnPPA) [
16]. SnPPA could mediate the photoreduction by electron transfer to cleave the azobenzene moiety and thus activate the siRNA prodrug (
Figure 1).
In preliminary tests, an RF-DNA model strand (DNA
1) was synthesized, characterized, and its stability in the presence of various potentially reactive molecules found in the intracellular environment (H
2O
2, NaSH, KO
2, sodium ascorbate) was confirmed. In contrast, we observed that DNA
1 is indeed activated upon irradiation with red light in the presence of photosensitizer SnPPA and ascorbate as an electron source. Next, the RF-RNA guide strand (RNA
2) was synthesized and its similar to DNA
1 behavior was confirmed in cell-free settings. Finally, the corresponding siRNA prodrug (RNA
2/
3) was assembled. As gene target,
KIF11 was chosen because it is an essential gene for mitosis that is overexpressed in some cancers, making it a promising target for cancer treatment [
17]. We investigated the RNAi efficiency of the siRNA prodrug in human ovarian carcinoma cells A2780 by reverse transcription quantitative PCR (RT-qPCR) in the presence and absence of the photosensitizer SnPPA, showing selective activation and good knockdown efficiency upon irradiation with red light.
Figure 1.
State-of-the-art in siRNA prodrugs. The 9-anthracenyl promoiety on the guide strand of the siRNA is cleaved by 1O2 that is photogenerated on the passenger strand upon red-light irradiation. The 1O2, as well as the anthraquinone side product, are potentially harmful to the cells and the surrounding tissue. In this work, we report on an improved siRNA prodrug, which does not require 1O2 for the activation: it is activated upon red light-induced electron transfer in the presence of photosensitizer SnPPA.